Royal Philips


The Dutch giant now poised for much better times

29/04/24 -"While our earnings estimates have reset higher, the extent of the upgrade is limited compared with the fundamental metrics (DCF and NAV) given that our numbers are already on the high side when ..."

Pages
63
Language
English
Published on
29/04/24
You may also be interested by these reports :
16/05/24
On the back of the promising beginning to 2024, which was a combination of 1/ normalising market demand in Europe (the lynchpin geography); 2/ the ...

16/05/24
As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from ...

15/05/24
Bastide reported stronger organic growth in Q3 than in the previous two quarters. The group is currently spinning off two Swiss subsidiaries, which ...

15/05/24
Orpea published overall good-looking organic revenue in the Q1, primarily led by improvements in the international performance while its activities ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO